Daily Sepsis Research Analysis
Analyzed 35 papers and selected 3 impactful papers.
Summary
Three high-impact studies on sepsis highlight: (1) dynamic serum osmolality trajectories independently predict mortality and support precision fluid therapy; (2) an umbrella meta-analysis suggests perioperative probiotics/synbiotics reduce postoperative infections, including sepsis; and (3) U.S. practice data show IV vitamin C use in sepsis remained rare and declined as trial evidence emerged, illustrating de-implementation dynamics.
Research Themes
- Trajectory-guided precision fluid therapy in sepsis
- Perioperative microbiome modulation to reduce postoperative sepsis
- Evidence-driven de-implementation of low-value sepsis treatments
Selected Articles
1. Association between serum osmolality trajectories and mortality in sepsis patients: a retrospective multi-cohort study.
Among 22,737 ICU patients with sepsis across MIMIC-IV and eICU-CRD with external validation (n=303), three 4-day serum osmolality trajectories (stable, ascending, descending) were identified. Ascending and descending trajectories conferred markedly higher 28-day mortality (HR≈1.8), partially mediated by renal dysfunction and cumulative positive fluid balance. Parametric g-formula simulations indicated trajectory-specific heterogeneity in optimal fluid strategies.
Impact: This study operationalizes dynamic osmolality as a prognostic biomarker and links it to modifiable pathways (renal function, fluid balance), providing a concrete framework for precision fluid therapy in sepsis.
Clinical Implications: Monitor osmolality trajectories early in ICU sepsis and consider trajectory-guided, individualized fluid strategies, especially in patients showing rising or falling osmolality patterns that signal higher mortality risk.
Key Findings
- Identified three 4-day serum osmolality trajectories (stable, ascending, descending) in 22,737 septic ICU patients.
- Ascending and descending trajectories independently predicted higher 28-day mortality (HR 1.80 and 1.83, respectively).
- Renal dysfunction (11.16%) and cumulative positive fluid balance (11.39%) partially mediated the mortality association.
- Parametric g-formula simulations revealed trajectory-specific heterogeneity in responses to fluid management.
Methodological Strengths
- Large, multi-cohort dataset with external validation and consistent signal across databases.
- Advanced analytics including latent class trajectory modeling, mediation analysis, and parametric g-formula simulations.
Limitations
- Retrospective observational design with potential residual confounding and selection bias.
- Measurement timing/frequency of osmolality may vary across centers; external validation cohort was relatively small (n=303).
Future Directions: Prospective interventional trials testing trajectory-guided fluid therapy; integration of osmolality trajectories into EHR-based decision support for early risk stratification.
BACKGROUND: Sepsis commonly leads to fluid and electrolyte imbalances, often reflected in abnormal serum osmolality. Although static measurements of osmolality have been investigated, the prognostic significance of dynamic changes in serum osmolality over time remains poorly understood in patients with sepsis. METHODS: We conducted a comprehensive analysis of 22,737 septic patients from the MIMIC-IV and eICU-CRD databases, with external validation performed using an independent cohort of 303 patients from Zhejiang Provincial People's Hospital. Latent class trajectory modeling was applied to identify distinct patterns of serum osmolality during the first 4 days in the ICU. The association between trajectory patterns and mortality was assessed using Cox proportional hazards regression. Mediation analysis was employed to explore potential biological mechanisms, while parametric g-formula simulations were used to evaluate the impact of trajectory-specific fluid management strategies. RESULTS: Three distinct serum osmolality trajectories were identified: stable (ST), ascending (AS), and descending (DS). Compared to the ST group, both the AS and DS groups were associated with significantly higher 28-day mortality (HR 1.80, 95% CI 1.61-2.01 for AS; HR 1.83, 95% CI 1.62-2.06 for DS). Mediation analysis indicated that renal dysfunction (accounting for 11.16% of the total effect, P < 0.001) and cumulative positive fluid balance (11.39%, P < 0.001) partially mediated the observed associations. Parametric g-formula simulations revealed substantial heterogeneity in responses to fluid management across trajectory groups, with optimal fluid strategies varying significantly by trajectory pattern and patient characteristics. CONCLUSION: Dynamic serum osmolality trajectories are independent predictors of mortality in sepsis, with effects partially mediated through renal dysfunction and fluid imbalance. These findings support the implementation of trajectory-guided precision fluid therapy as a novel framework for individualized sepsis care, challenging one-size-fits-all approaches and offering evidence-based guidance for personalized treatment strategies.
2. Beneficial Impacts of pre- and Postoperative Probiotics/Synbiotics Supplementation in Patients Undergoing Gastrointestinal Surgeries: An Umbrella Meta-Analysis.
An umbrella meta-analysis of 17 meta-analyses found that perioperative probiotics/synbiotics significantly reduced postoperative infections (including sepsis), shortened hospital stay, decreased diarrhea, lowered mortality, and reduced antibiotic duration. Benefits were particularly notable for preoperative-only regimens in liver surgery and in patients under 60, with overall moderate-to-high methodological quality.
Impact: Synthesizing higher-level evidence across meta-analyses, this study strengthens the case for incorporating microbiome-targeted adjuncts into perioperative care to reduce postoperative sepsis and related complications.
Clinical Implications: Consider perioperative probiotic/synbiotic supplementation as adjuncts within enhanced recovery protocols for GI surgeries, with attention to strain selection, dosing, and patient factors (e.g., liver surgery, age <60) while monitoring for risks in immunocompromised patients.
Key Findings
- Reduced postoperative infections including sepsis (OR 0.48, 95% CI 0.42-0.53).
- Shortened hospital stay (SMD -0.95), decreased diarrhea (OR 0.37), lower mortality (OR 0.48), and shorter antibiotic duration (SMD -1.87).
- Preoperative-only supplementation showed particular benefits in liver surgeries and in patients <60 years.
Methodological Strengths
- Umbrella meta-analysis following PRISMA with AMSTAR 2 quality appraisal across 17 meta-analyses.
- Comprehensive bias and heterogeneity assessment (random-effects models, I², subgroup/sensitivity analyses, trim-and-fill).
Limitations
- Heterogeneity in strains, doses, durations, and surgical contexts across included studies.
- Potential publication bias and variable quality of underlying primary studies within included meta-analyses.
Future Directions: Standardize probiotic/synbiotic regimens (strain, dose, duration) and conduct large, high-quality RCTs targeting prespecified infections including sepsis in defined surgical subpopulations.
Probiotics and synbiotics may help reduce complications following gastrointestinal (GI) surgeries by restoring microbial balance and modulating immune responses. This umbrella meta-analysis aimed to evaluate their effectiveness in improving pre- and postoperative outcomes. Following PRISMA guidelines, 17 meta-analyses were included after a comprehensive database search. Outcomes assessed included infection rates, hospital stay, diarrhea, mortality, and antibiotic use. Study quality was evaluated using the AMSTAR 2 tool. Pooled effect sizes were calculated using a random-effects model. Heterogeneity was quantified with the I² statistic and Cochrane's Q-test, and predefined subgroup analyses were conducted by intervention type, treatment duration, surgical complications, and patient condition. Sensitivity analyses evaluated result stability. Publication bias was assessed using funnel plots, Begg's and Egger's tests, with the trim-and-fill method applied where asymmetry was detected. Significantly reduced postoperative infections (OR = 0.48, 95% CI: 0.42-0.53), including surgical site infections, urinary tract infections, pulmonary infections, and sepsis. Supplementation also shortened hospital stays (SMD = - 0.95, 95% CI: - 1.79 to - 0.10), decreased the incidence of diarrhea (OR = 0.37, 95% CI: 0.23-0.50), lowered mortality (OR = 0.48, 95% CI: 0.13-0.82), and reduced antibiotic use duration (SMD = - 1.87, 95% CI: - 3.69 to - 0.05). Preoperative-only supplementation use was especially effective in liver surgeries and among patients under 60 years of age. The overall methodological quality was moderate to high in most included studies. Probiotic and synbiotic supplementation, particularly during the perioperative period, appears to be an effective strategy for reducing complications following gastrointestinal surgeries. These findings support their inclusion as adjunct therapies in enhanced recovery protocols.
3. Trends in Use of IV Vitamin C Among Patients With Sepsis.
In a 14-year analysis of 11,375,326 U.S. sepsis hospitalizations, only 0.3% received IV vitamin C. Use rose after a 2016 before-after study, peaked in Q1 2020, and declined through 2021 as RCT evidence emerged; between-hospital variation was substantial (median odds ratio 7.78).
Impact: This study quantifies real-world adoption and subsequent de-implementation of IV vitamin C in sepsis at national scale, aligning utilization with evolving evidence and highlighting wide inter-hospital variability.
Clinical Implications: Given low and declining use aligned with trial evidence, routine IV vitamin C for sepsis should be avoided outside trials; targeted de-implementation and stewardship can reduce low-value care and practice variation.
Key Findings
- Across 11,375,326 sepsis hospitalizations, 0.3% received IV vitamin C at any time.
- Utilization peaked at 0.6% in Q1 2020 and fell to 0.1% by Q4 2021 as trial evidence emerged.
- Substantial between-hospital variability (median odds ratio 7.78) persisted across subcohorts.
Methodological Strengths
- Massive, national, multi-hospital dataset with prespecified time cutpoints and multilevel modeling.
- Consistency of temporal patterns across sicker subgroups and in a hospital-random-effects analysis.
Limitations
- Observational design without patient-level outcome effects of vitamin C; dosing and timing regimens not captured.
- Potential misclassification around sepsis coding transitions and unmeasured confounding in utilization patterns.
Future Directions: Link utilization to patient-centered outcomes and costs; evaluate de-implementation strategies and institutional drivers of variation.
OBJECTIVES: We sought to determine trends in use of IV vitamin C for hospitalized patients with sepsis in the context of evolving evidence, including a single-center before-after study in late 2016 and several trials in 2019-2021. DESIGN: Retrospective cohort study. SETTING: One thousand one hundred fifteen U.S. hospitals contributing to the Premier Healthcare Database, 2008-2021. PATIENTS: Eleven million three hundred seventy-five thousand three hundred twenty-six adult inpatients with sepsis. INTERVENTIONS: IV vitamin C, at any point of the hospital stay. MEASUREMENTS AND MAIN RESULTS: Patients had a median (interquartile range [IQR]) age of 71 years (59-81 yr) and a median (IQR) of 5 comorbidities (4-7 comorbidities); 53.0% were female; on hospital day 1, 6.9% were mechanically ventilated and 7.5% received a vasopressor. Overall, 32,131 patients (0.3%) received IV vitamin C at any point during hospitalization. During the study period, administration fell from 2008, quarter 1 (0.5%) through 2017, quarter 1 (< 0.1%), then rose and peaked in 2020, quarter 1 (0.6%), and fell through 2021, quarter 4 (0.1%). Examining three time periods defined by predetermined cutpoints (2015 quarter 4, when International Classification of Diseases coding for sepsis changed, and 2020 quarter 1, when the COVID-19 pandemic began), vitamin C use also varied (p < 0.001): 0.2% (2008 quarter 1 to 2015 quarter 3); 0.3% (2015 quarter 4 to 2019 quarter 4); and 0.3% (2020-2021). Temporal trends were similar in sicker subcohorts defined by early mechanical ventilation, early vasopressor use, and diagnosis of COVID-19 (2020-2021). A multilevel logistic regression model with data from 91 hospitals that contributed at least 1 sepsis case per quarter showed a similar utilization pattern, with substantial between-hospital variability (median odds ratio, 7.78; 95% CI, 5.45-11.58). CONCLUSIONS: IV vitamin C prescription for hospitalized patients with sepsis in the United States was overall infrequent over the 14-year study period, rising after the publication of a before-after study and declining in the COVID-19 pandemic as clinical trial results emerged.